Single Technologies AB

Single Technologies AB is a pioneering company specializing in advanced genomic analysis with its 3-D Sequencing™ platform, Theta, which dramatically enhances DNA sequencing capabilities. Single Technologies AB, founded in 2014, is based in Stockholm, Sweden, and focuses on innovative genomic analysis solutions. The company has undergone strategic pivots to refine its technology and market approach. Notably, KTH Holding recently exited its stake in the firm.

The founder's background includes previous ventures in the biotechnology sector. Single Technologies specializes in advanced genomic analysis through its flagship product, the 3-D Sequencing™ platform, known as Theta. This innovative technology enables three-dimensional sequencing, which significantly enhances data throughput and allows for massive parallelism in both in situ and solution-based DNA sequencing. The core functionality of Theta provides researchers and innovators with a tool to read vast quantities of DNA simultaneously, unlocking intricate cellular insights by sequencing directly within cells.

This capability is particularly advantageous for applications in genomics and proteomics, catering to the needs of academic institutions, biotechnology companies, and healthcare organizations focused on research and development. The company primarily serves markets in Europe, North America, and Asia, aiming to empower scientific advancements globally. Single Technologies generates revenue through partnerships and direct sales of its 3-D Sequencing™ platform, targeting B2B clients in the academic and biotechnology sectors. Transactions involve the provision of equipment, maintenance services, and access to proprietary software that supports data analysis and interpretation.

These transactions may include subscription models for software updates and analytics tools, ensuring ongoing client support and engagement. Pricing structures are tailored to the specific needs of clients, reflecting the advanced nature of the technology and its applications in biological research. The company's strategic focus on collaboration with leading researchers and innovators positions it as a key player in the field of genomics, facilitating mutually beneficial relationships that drive revenue growth. Single Technologies plans to introduce new products designed to enhance genomic analysis capabilities in the near future.

The company is also targeting expansion into new markets in Asia and North America by the end of 2024. Recent funding of USD 0. 687 mn will support these initiatives, further enabling development and market penetration.